Hunterase ICV Receives Marketing Approval in Peru
-
Hunterase ICV obtained marketing approval from Peruvian drug authority DIGEMID for Hunter syndrome (MPS II) on April 30, 2026.
-
Intracerebroventricular administration via device targets CNS damage.
-
Approximately 70% of Hunter syndrome patients are severe type with CNS involvement.
-
Planned launch in Peru in 2027.
KOSPI Filing Information
-
Filing: Investment Decision Related Key Management Matters
-
Company: GC Biopharma (006280)
-
Submission: GC Biopharma Corp.
-
Receipt: 05-06-2026
-
Under KRX KOSPI Market Division